These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 30452687)
1. Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer. Miyamoto S; Nomura R; Sato K; Awano N; Kuse N; Inomata M; Izumo T; Terada Y; Furuhata Y; Bae Y; Kunitoh H Jpn J Clin Oncol; 2019 Feb; 49(2):160-164. PubMed ID: 30452687 [TBL] [Abstract][Full Text] [Related]
2. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial. Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637 [TBL] [Abstract][Full Text] [Related]
3. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D Lung Cancer; 2019 Jul; 133():83-87. PubMed ID: 31200833 [TBL] [Abstract][Full Text] [Related]
4. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer. Ajlouni M; Chapman R; Kim JH Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551 [TBL] [Abstract][Full Text] [Related]
5. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312 [TBL] [Abstract][Full Text] [Related]
6. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. Bestvina CM; Pointer KB; Karrison T; Al-Hallaq H; Hoffman PC; Jelinek MJ; Juloori A; Melotek JM; Murgu S; Partouche J; Vokes EE; Weichselbaum RR; Pitroda SP; Patel JD; Chmura SJ J Thorac Oncol; 2022 Jan; 17(1):130-140. PubMed ID: 34500113 [TBL] [Abstract][Full Text] [Related]
7. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer. Mattes MD; Eubank TD; Almubarak M; Wen S; Marano GD; Jacobson GM; Ma PC Clin Lung Cancer; 2021 Jul; 22(4):268-273. PubMed ID: 33608212 [TBL] [Abstract][Full Text] [Related]
8. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up. Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929 [TBL] [Abstract][Full Text] [Related]
9. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. Altan M; Wang Y; Song J; Welsh J; Tang C; Guha-Thakurta N; Blumenschein GR; Carter BW; Wefel JS; Ghia AJ; Yeboa DN; McAleer MF; Chung C; Woodhouse KD; McGovern SL; Wang C; Kim BYS; Weinberg JS; Briere TM; Elamin YY; Le X; Cascone T; Negrao MV; Skoulidis F; Ferrarotto R; Heymach JV; Li J J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37402581 [TBL] [Abstract][Full Text] [Related]
10. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. Ahmed KA; Kim S; Arrington J; Naghavi AO; Dilling TJ; Creelan BC; Antonia SJ; Caudell JJ; Harrison LB; Sahebjam S; Gray JE; Etame AB; Johnstone PA; Yu M; Perez BA J Neurooncol; 2017 Jun; 133(2):331-338. PubMed ID: 28466250 [TBL] [Abstract][Full Text] [Related]
11. Outcome Study of Cobalt Based Stereotactic Body Radiation Therapy for Patients with Inoperable Stage III Non-small Cell Lung Cancer. Wang Y; Lan F; Kang X; Shao Y; Li H; Li P; Wu W; Wang J; Chang D; Wang Y; Xia T Technol Cancer Res Treat; 2015 Oct; 14(5):539-45. PubMed ID: 24750001 [TBL] [Abstract][Full Text] [Related]
12. [Stereotactic body radiaton therapy for 15 patients with small lung neoplasms]. Yu R; Li Y; Zhu G Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):266-70. PubMed ID: 21426671 [TBL] [Abstract][Full Text] [Related]
13. Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Yamaguchi O; Kaira K; Hashimoto K; Mouri A; Miura Y; Shiono A; Nishihara F; Murayama Y; Noda SE; Kato S; Kobayashi K; Kagamu H Thorac Cancer; 2019 Apr; 10(4):992-1000. PubMed ID: 30888716 [TBL] [Abstract][Full Text] [Related]
14. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394 [TBL] [Abstract][Full Text] [Related]
15. Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors. Collins BT; Erickson K; Reichner CA; Collins SP; Gagnon GJ; Dieterich S; McRae DA; Zhang Y; Yousefi S; Levy E; Chang T; Jamis-Dow C; Banovac F; Anderson ED Radiat Oncol; 2007 Oct; 2():39. PubMed ID: 17953752 [TBL] [Abstract][Full Text] [Related]
16. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. Galli G; Proto C; Cossa M; Valeri B; Sdao S; Signorelli D; Imbimbo M; de Braud F; Garassino MC; Lo Russo G Tumori; 2019 Dec; 105(6):NP57-NP62. PubMed ID: 31456503 [TBL] [Abstract][Full Text] [Related]
17. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial. Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249 [TBL] [Abstract][Full Text] [Related]
18. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC. Lesueur P; Escande A; Thariat J; Vauléon E; Monnet I; Cortot A; Lerouge D; Danhier S; Dô P; Dubos-Arvis C; Chouaïd C; Gervais R Cancer Med; 2018 Nov; 7(11):5505-5513. PubMed ID: 30311424 [TBL] [Abstract][Full Text] [Related]
19. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies. Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840 [TBL] [Abstract][Full Text] [Related]
20. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]